[{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Large Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"SRB21","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ Debiopharm"},{"orgOrder":0,"company":"MEDSIR","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"MEDSIR","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDSIR \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"MEDSIR \/ Debiopharm"},{"orgOrder":0,"company":"Ona Therapeutics","sponsor":"Fund+","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ona Therapeutics \/ Fund+","highestDevelopmentStatusID":"4","companyTruncated":"Ona Therapeutics \/ Fund+"},{"orgOrder":0,"company":"SunRock Biopharma","sponsor":"Ellipses Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"SRB22","moa":"HER3","graph1":"Oncology","graph2":"Preclinical","graph3":"SunRock Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunRock Biopharma \/ Ellipses Pharma Limited","highestDevelopmentStatusID":"4","companyTruncated":"SunRock Biopharma \/ Ellipses Pharma Limited"},{"orgOrder":0,"company":"Oncomatryx","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibody-drug Conjugate","year":"2022","type":"Financing","leadProduct":"OMTX705","moa":"FAP-alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Oncomatryx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncomatryx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oncomatryx \/ Undisclosed"},{"orgOrder":0,"company":"EntreChem","sponsor":"AI Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"AIT-102","moa":"SWI\/SNF","graph1":"Oncology","graph2":"Preclinical","graph3":"EntreChem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EntreChem \/ AI Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"EntreChem \/ AI Therapeutics"},{"orgOrder":0,"company":"Viralgen","sponsor":"Trogenix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"TGX-007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viralgen \/ Trogenix","highestDevelopmentStatusID":"4","companyTruncated":"Viralgen \/ Trogenix"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The collaboration aims to advance the clinical development of Trogenix's rAAV gene therapy, TGX-007, which is being evaluated for glioblastoma.

                          Product Name : TGX-007

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 06, 2025

                          Lead Product(s) : TGX-007

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Trogenix

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The collaboration aims to evaluate the safety and efficacy of Debio 0123, Debiopharm's investigational, potential best-in-class WEE1 inhibitor, together with Trodelvy (sacituzumab govitecan).

                          Product Name : Debio 0123

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 28, 2024

                          Lead Product(s) : Debio 0123,Sacituzumab Govitecan

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Debiopharm

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody dr...

                          Product Name : SRB21

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          September 21, 2023

                          Lead Product(s) : SRB21

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Debiopharm

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.

                          Product Name : EP0017

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          May 25, 2022

                          Lead Product(s) : SRB22

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ellipses Pharma Limited

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.

                          Product Name : AIT-102

                          Product Type : Antibiotic

                          Upfront Cash : Undisclosed

                          April 25, 2022

                          Lead Product(s) : AIT-102

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : AI Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : These funds, together with Oncomatryx recurring revenues from its licensing agreements with international biopharmaceutical companies, will be used for the clinical development of additional ADCs of Oncomatryx tumour-microenvironment pipeline including O...

                          Product Name : OMTX705

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          April 22, 2022

                          Lead Product(s) : OMTX705

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $16.0 million

                          Deal Type : Financing

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 16, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Fund+

                          Deal Size : $33.6 million

                          Deal Type : Series A Financing

                          blank